

AETHLON MEDICAL, INC.

BIO INVESTOR FORUM

NASDAQ: AEMD

TIMOTHY C. RODELL, M.D., CHIEF EXECUTIVE OFFICER

OCTOBER 23, 2019



FORWARD LOOKING STATEMENTS

The following presentation may contain predictions, estimates, and other forward looking statements that involve risks and uncertainties, including whether and when our products are successfully developed and introduced; market acceptance of the Aethlon Hemopurifier[®] and other product offerings; regulatory delays, manufacturing delays, and other risks detailed in our SEC filings, which are accessible at www.sec.gov or on our website: www.AethlonMedical.com

AETHLON MEDICAL, INC.

MEDICAL DEVICES FOR CANCER AND VIRAL DISEASES

- HEMOPURIFIER®
- EXOSOME SCIENCES, INC.
 - 80% OWNED SUBSIDIARY
 - DIAGNOSTICS FOR CANCER AND CTE

NASDAQ: AEMD

THE AETHLON HEMOPURIFIER®

DESIGNATED A "BREAKTHROUGH DEVICE" BY FDA



FDA DESIGNATED "BREAKTHROUGH DEVICE" FOR THE TREATMENT OF BOTH LIFE-THREATENING GLYCOSYLATED VIRUSES AND THE REMOVAL OF CANCER PROMOTING EXOSOMES

THE AETHLON HEMOPURIFIER®

USES ESTABLISHED DIALYSIS INFRASTRUCTURE



SELF-CONTAINED CLOSED SYSTEM UNDER DEVELOPMENT

THE AETHLON HEMOPURIFIER®

UNIQUE MECHANISM OF ACTION

COMBINATION MECHANISM OF ACTION


- SEPARATION BASED ON SIZE
- EXOSOMES AND VIRUSES ARE OF SIMILAR SIZE

LECTIN CAPTURE BASED ON GLYCOSYLATION (SUGARS)

- BOTH EXOSOMES AND MOST VIRUSES DISPLAY SAME SUGAR MOLECULES ON THEIR MEMBRANES
- LECTINS ARE PROTEINS THAT BIND SUGAR MOLECULES ON MEMBRANES



LECTINS BIND MEMBRANE SUGAR MOLECULES



Mannose (sugar) molecules in gray


HEMOPURIFIER® PROGRAMS

ONCOLOGY

- CLEARANCE OF CANCER PROMOTING EXOSOMES
- CHEMOTHERAPY RESISTANCE, PROMOTION OF METASTASIS, IMMUNE SUPPRESSION
- SYNERGISTIC WITH CHEMOTHERAPY, IMMUNOTHERAPY, TARGETED AGENTS
- MULTIPLE POTENTIAL CLINICAL TARGETS
 - BREAST, HEAD AND NECK, GASTROINTESTINAL, MELANOMA, ETC.
- WELL CHARACTERIZED MARKETS, DEVELOPMENT PATHWAYS AND ENDPOINTS

TUMOR-DERIVED EXOSOMES (TEX)

A SIGNIFICANT UNMET NEED IN CANCER CARE



Exosomes being released by a tumor cell

NATIONAL CANCER INSTITUTE (NCI) STUDIES

- PHASE I CONTRACT FROM NCI - COMPLETED

“DEVICE STRATEGY FOR DIFFERENTIAL ISOLATION OF ONCOSOMES AND NON-MALIGNANT EXOSOMES”

- ONGOING NCI SBIR GRANT

“THE HEMOPURIFIER® DEVICE FOR TARGETED REMOVAL OF BREAST CANCER EXOSOMES FROM THE BLOOD CIRCULATION”

- SEPTEMBER 2019 – PHASE II NCI SBIR CONTRACT

\$1.8 MILLION OVER 2 YEARS

“TECHNOLOGIES FOR DIFFERENTIAL ISOLATION OF EXOSOMES AND ONCOSOMES”

HEMOPURIFIER DEVELOPMENT UPDATE

- MANUFACTURING
 - NEW CMO QUALIFIED
- REGULATORY
 - IDE FOR VIRAL INDICATIONS ACTIVE
 - EXPANDED ACCESS PROTOCOL APPROVED IN U.S. AND CANADA
 - ONCOLOGY IDE APPROVED OCTOBER 2019
- CLINICAL
 - EARLY FEASIBILITY STUDY (EFS) IN HEAD AND NECK CANCER BEING INITIATED

BREAKTHROUGH DESIGNATION IDE "SPRINT" REVIEW

- FILED SEPTEMBER 5TH
- FIRST ROUND OF COMMENTS 3 DAYS LATER
- SIX ADDITIONAL ROUNDS OF COMMENTS
 - SEVEN AMENDMENTS FILED IN 25 DAYS
- APPROVED OCTOBER 4TH
 - NOTIFIED @ 4 PM ON LAST DAY OF REVIEW CYCLE

HEMOPURIFIER® PROGRAMS

ONCOLOGY

- CLEARANCE OF CANCER PROMOTING EXOSOMES
- SYNERGISTIC WITH CHEMOTHERAPY, IMMUNOTHERAPY, TARGETED AGENTS
- MULTIPLE POTENTIAL CLINICAL TARGETS
 - BREAST, HEAD AND NECK, GASTROINTESTINAL, MELANOMA, ETC.
- WELL-CHARACTERIZED MARKETS, DEVELOPMENT PATHWAYS AND ENDPOINTS

VIRAL

- ALL GLYCOSYLATED VIRUSES POTENTIALLY CAN BE CLEARED BY HEMOPURIFIER®
- FDA GRANTED EXPANDED ACCESS FOR EBOLA IN U.S. AND HEALTH CANADA GRANTED EQUIVALENT IN CANADA
- OTHER VIRAL TARGETS

EXOSOME SCIENCES, INC.

DIAGNOSTICS BASED ON EXOSOME DETECTION AND CHARACTERIZATION

- EXOSOMAL TAU PROTEIN CORRELATES WITH EXPOSURE TO TRAUMA IN NFL PLAYERS
- *J. ALZHEIMERS Dis. 2016*
- CONFIRMATORY STUDY ONGOING AT TGEN
- POTENTIAL DIAGNOSTIC FOR CTE IN LIVING PLAYERS
- ONCOLOGY APPLICATIONS IN DEVELOPMENT
- COLLABORATION WITH HOAG HOSPITAL SYSTEMS – SEPTEMBER 2019
- IDENTIFICATION OF EXOSOMAL MARKERS OF CANCER RISK & PROGRESSION

SUMMARY

- UNIQUE HEMOPURIFIER® BLOOD PURIFICATION DEVICE
- TWO FDA BREAKTHROUGH DESIGNATIONS
- MULTIPLE THERAPEUTIC TARGETS IN CANCER AND VIRAL DISEASE
- MANAGEMENT TEAM WITH OVER 100 YEARS HEALTHCARE EXPERIENCE
- EXOSOME SCIENCES SUBSIDIARY
 - DIAGNOSTICS IN CANCER AND NEURODEGENERATIVE DISEASE
- NASDAQ: AEMD



9635 Granite Ridge Drive, Suite 100
San Diego, California 92123
858.459.7800
Nasdaq: AEMD

www.AethlonMedical.com

This presentation may contain predictions, estimates, and other forward looking statements that involve risks and uncertainties, including whether and when our products are successfully developed and introduced; market acceptance of the Aethlon Hemopurifier[®] and other product offerings; regulatory delays, manufacturing delays, and other risks detailed in our SEC filings, which are accessible at www.sec.gov or on our website: www.AethlonMedical.com

SEASTAR CROSS LICENSE AGREEMENT

- EXECUTED JULY 2019
- CROSS LICENSE TO SEASTAR CARTRIDGES AND HEMOPURIFIER®
- PROVIDES FOR CO-DEVELOPMENT TO EXPAND TARGET MARKETS
- INITIAL TARGETS ORGAN PRESERVATION AND TRANSPLANT

AETHLON LEADERSHIP

TIMOTHY C. RODELL, M.D., CHIEF EXECUTIVE OFFICER

- PHYSICIAN SCIENTIST WITH > 30 YEARS OF DEVELOPMENT EXPERIENCE IN PUBLIC & PRIVATE COMPANIES, 3 IPOs IN U.S. AND ABROAD, 10 PRODUCTS FROM BENCH THROUGH LATE STAGE CLINICAL TRIALS

CHARLES J. FISHER, JR., M.D., CHAIRMAN

- ACADEMIC & INDUSTRY THOUGHT LEADER IN SEPSIS & INFLAMMATION
- HEAD OF CRITICAL CARE - CLEVELAND CLINIC
- SENIOR EXECUTIVE - LILLY, ABBOTT, CARDIOME

JAMES B. FRAKES, CHIEF FINANCIAL OFFICER

- 29 YEARS OF PUBLIC COMPANY CFO EXPERIENCE, INVESTMENT BANKING & VC